However, despite the published evidence demonstrating the benefits of using genetic tests, the first-tier diagnosis of HAE only involves plasma measurements separately in a period of 1–3 months of the C4 and C1-INH protein levels and of the C1-INH function (Caballero et al., 2011a). This evidence concerns the gene C4A and hereditary angioedema.